Bayer CropScience Ltd Q2 FY26 results (latest), Jul–Sep 2025 →Revenue ₹1,553 Cr −10.6% YoYSee revenue, profit and what management said. You are viewing Q4 FY19.
BC

Bayer CropScience Ltd

Q4 FY19Fertilizers & Agrochemicals

Bayer CropScience Q4 FY19 earnings call: Revenue & Margins

Q4 FY19 investor presentation: what the company reported on revenue, margins and capex.

Bayer CropScience Ltd Q4 FY19 key numbers

Revenue
Q1 2019 Crop Science segment sales: €6,444 million, +5.5% year-on-year (YoY) currency- and portfolio-adjusted.

As stated in Bayer CropScience Ltd's Q4 FY19 investor presentation · published 24 Sept 2026. Reported figures, not investment advice.

Based on Bayer CropScience Ltd's Q4 FY19 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹3,736
Market cap₹17.0K Cr
P/E23.2

The short version

Q1 2019 Crop Science segment sales: €6,444 million, +5.5% year-on-year (YoY) currency- and portfolio-adjusted - Pharmaceuticals sales: €4,354 million, +5.3% YoY

From Bayer CropScience Ltd's Q4 FY19 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • Q1 2019 Crop Science segment sales: €6,444 million, +5.5% year-on-year (YoY) currency- and portfolio-adjusted
  • Pharmaceuticals sales: €4,354 million, +5.3% YoY
  • Consumer Health sales: €1,395 million, –1.4% YoY
  • Animal Health sales: €421 million, –0.9% YoY
  • Crop Science EBITDA before special items grew +122.8% YoY

2 more points from Bayer CropScience Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Bayer CropScience Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

See what Bayer CropScience Ltd said on capital expenditure plans — free account, 30 seconds.

Top-ranked in Fertilizers & Agrochemicals

Ranked on what management guided this quarter

Guidance-ranked
1Anya Polytech &
Rev 2Mar 1
Rev 2Mar 2
3
Rev 2Mar 3
4
Rev 2Mar 3
5
Rev 3Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Bayer CropScience Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Bayer CropScience Ltd said on order book & pipeline — free account, 30 seconds.

Bayer CropScience Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26

Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹1.1K Cr, net profit ₹162 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Bayer CropScience Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Bayer CropScience Ltd Q4 FY19 results?

Q1 2019 Crop Science segment sales: €6,444 million, +5.5% year-on-year (YoY) currency- and portfolio-adjusted - Pharmaceuticals sales: €4,354 million, +5.3% YoY

What is Bayer CropScience Ltd share price analysis?

Bayer CropScience Ltd currently shows a neutral. The stock trades at a P/E of 23.2 with a market cap of ₹16,986 Cr. Investors should review the full earnings analysis for detailed insights.

Keep Bayer CropScience Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.